AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14513918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10714402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose clonazepam (CZP) 0.02 mg/kg BW
Number of subjects: 15
Study 10714402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9139555 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 70
Study 9139555 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 70
Study 10146966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mesalazine (mesalamine) at 1g, 2g, or 4g daily
Number of subjects: 374
Study 10146966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 3003144 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 28
Study 3003144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31563122 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution
Number of subjects: 17
Study 31563122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificially flavored)
Number of subjects: 17
Study 29531764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 24
Study 29531764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27428073 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumour lysate dendritic cell vaccine (ADC) + best supportive care (BSC)
Number of subjects: 52
Study 27428073 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 52
Study 27428073 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with ADC
Number of subjects: 52
Study 25498484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment initiated within 3 hours of injury
Number of subjects: 20211
Study 25498484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment initiated beyond 3 hours of injury
Number of subjects: 20211
Study 23424892 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn tortilla fortified with 20 mg/kg of zinc oxide
Number of subjects: 10
Study 23424892 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn tortilla fortified with 20 mg/kg of zinc sulfate
Number of subjects: 10
Study 23424892 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfortified corn tortilla
Number of subjects: 10
Study 23424892 — intervention group
Group type: COMPARATOR
Intervention: Corn tortilla with no iron added
Number of subjects: 10
Study 23424892 — intervention group
Group type: COMPARATOR
Intervention: Corn tortilla with 30 mg/kg of iron added
Number of subjects: 10
Study 23424892 — intervention group
Group type: COMPARATOR
Intervention: Corn tortilla with 60 mg/kg of iron added
Number of subjects: 10
Study 20450653 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 75
Study 20450653 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 18715434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa butter lotion
Number of subjects: 210
Study 18715434 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 210
Study 20428365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment for all household members
Number of subjects: 132
Study 20428365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 132
Study 16354359 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgical excision
Number of subjects: 50
Study 16354359 — intervention group
Group type: COMPARATOR
Intervention: Cold knife excision
Number of subjects: 50
Study 16354359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 12040811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring program
Number of subjects: 0
Study 9845867 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-link mapping enhanced counseling
Number of subjects: 360
Study 9845867 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 360
Study 7985509 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular attenders (Group A)
Number of subjects: 8310
Study 7985509 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold restorations
Number of subjects: 8310
Study 7985509 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 8310
Study 7985509 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restorations
Number of subjects: 8310
Study 7985509 — intervention group
Group type: COMPARATOR
Intervention: All restorations
Number of subjects: 8310
Study 2661435 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 38560A 50 micrograms/kg
Number of subjects: 15
Study 2661435 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 38560A 125 micrograms/kg
Number of subjects: 15
Study 2661435 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 38560A 250 micrograms/kg
Number of subjects: 15
Study 31422414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-gene combination
Number of subjects: 19
Study 29573538 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist (PT) follow-up
Number of subjects: 68
Study 29573538 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist (RT) follow-up
Number of subjects: 68
Study 27080120 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day ART initiation
Number of subjects: 260
Study 27080120 — intervention group
Group type: COMPARATOR
Intervention: Standard of care pre-ART assessment and counselling
Number of subjects: 260
Study 23253191 — intervention group
Group type: EXPERIMENTAL
Intervention: ModNa(+) (82 mM Na+)
Number of subjects: 10
Study 23253191 — intervention group
Group type: EXPERIMENTAL
Intervention: HighNa(+) (164 mM Na+)
Number of subjects: 10
Study 23253191 — intervention group
Group type: COMPARATOR
Intervention: CON (water alone)
Number of subjects: 10
Study 23253191 — intervention group
Group type: EXPERIMENTAL
Intervention: ModNa(+) and HighNa(+)
Number of subjects: 10
Study 22288920 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 N tongue training
Number of subjects: 16
Study 22288920 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 N tongue training
Number of subjects: 16
Study 22288920 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS training
Number of subjects: 16
Study 22288920 — intervention group
Group type: COMPARATOR
Intervention: Control experiment (experienced group)
Number of subjects: 16
Study 22288920 — intervention group
Group type: COMPARATOR
Intervention: Control experiment (naive group)
Number of subjects: 16
Study 22288920 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS training vs simple tongue training
Number of subjects: 16
Study 20943454 — intervention group
Group type: EXPERIMENTAL
Intervention: CON‐IFN plus lamivudine combination therapy
Number of subjects: 9
Study 20943454 — intervention group
Group type: COMPARATOR
Intervention: lamivudine monotherapy
Number of subjects: 9
Study 20943454 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN plus lamivudine combination therapy
Number of subjects: 9
Study 17227819 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 60
Study 17227819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 16114156 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once daily (n=125)
Number of subjects: 250
Study 16114156 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 4 mg daily (n=125)
Number of subjects: 250
Study 16114156 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 250
Study 16114156 — intervention group
Group type: COMPARATOR
Intervention: Perindopril
Number of subjects: 250
Study 11950109 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 55
Study 11950109 — intervention group
Group type: COMPARATOR
Intervention: Bottle-feeding
Number of subjects: 55
Study 10069877 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Outreach Program (AOP)
Number of subjects: 57
Study 10069877 — intervention group
Group type: COMPARATOR
Intervention: Control group (single intensive asthma education intervention)
Number of subjects: 57
Study 10069877 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AOP vs Control
Number of subjects: 57
Study 7732341 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance in screening for colorectal cancer with faecal occult blood testing
Number of subjects: 34144
Study 7732341 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-attenders
Number of subjects: 34144
Study 7732341 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenders
Number of subjects: 34144
Study 2325572 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose calcitriol (0.25 micrograms twice daily)
Number of subjects: 636
Study 2325572 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (1,000 mg/d)
Number of subjects: 636
Study 6997734 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular dose of aqueous penicillin G given at birth
Number of subjects: 18738
Study 31772545 — intervention group
Group type: EXPERIMENTAL
Intervention: Slender sheath
Number of subjects: 1000
Study 31772545 — intervention group
Group type: COMPARATOR
Intervention: Standard sheath
Number of subjects: 1000
Study 31772545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1000
Study 24866894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.6µg/kg/hour)
Number of subjects: 60
Study 24866894 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 60
Study 25636764 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with irradiation to the internal mammary lymph node (IMN) (Arm 2)
Number of subjects: 0
Study 25636764 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without irradiation to the internal mammary lymph node (IMN) (Arm 1)
Number of subjects: 0
Study 24781178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsilgon N (herbal preparation)
Number of subjects: 62
Study 24781178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no herbal preparation)
Number of subjects: 62
Study 22113496 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (COX-2 inhibitor)
Number of subjects: 3
Study 19205027 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT intervention
Number of subjects: 58
Study 17293547 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding peer counseling (PC) intervention
Number of subjects: 0
Study 17293547 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15339467 — intervention group
Group type: EXPERIMENTAL
Intervention: Granules for nourishing kidney and strengthening brain (GNKSB)
Number of subjects: 90
Study 15339467 — intervention group
Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 90
Study 12080353 — intervention group
Group type: COMPARATOR
Intervention: 8 liters leukapheresis
Number of subjects: 40
Study 12080353 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 liters leukapheresis
Number of subjects: 40
Study 9833917 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red cells
Number of subjects: 16
Study 9833917 — intervention group
Group type: COMPARATOR
Intervention: Protein solution
Number of subjects: 16
Study 8125392 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding for 15 days
Number of subjects: 98
Study 8125392 — intervention group
Group type: COMPARATOR
Intervention: Parenteral feeding for 15 days
Number of subjects: 98
Study 8125392 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 98
Study 2573444 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐912 2.0 mg
Number of subjects: 8
Study 2573444 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐912 1.0 mg
Number of subjects: 8
Study 2573444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 795007 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg i.v. per day
Number of subjects: 57
Study 795007 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin 10 million I.U. 4 times a day and streptomycin 500 mg twice a day
Number of subjects: 57
Study 31770081 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (3 units/day for 2 weeks)
Number of subjects: 77
Study 31770081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vodka (3 units/day for 2 weeks)
Number of subjects: 77
Study 31770081 — intervention group
Group type: COMPARATOR
Intervention: Comparison between red wine and vodka
Number of subjects: 77
Study 30625297 — intervention group
Group type: EXPERIMENTAL
Intervention: NVR 3-778 plus pegIFN (600 mg twice daily)
Number of subjects: 73
Study 30625297 — intervention group
Group type: EXPERIMENTAL
Intervention: NVR 3-778 (≥1200 mg/d)
Number of subjects: 73
Study 30625297 — intervention group
Group type: COMPARATOR
Intervention: NVR 3-778 (100 mg, 200 mg, or 400 mg daily)
Number of subjects: 73
Study 30625297 — intervention group
Group type: COMPARATOR
Intervention: pegIFN alone
Number of subjects: 73
Study 28190122 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral incision
Number of subjects: 20
Study 28190122 — intervention group
Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 20
Study 25790848 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPACE (acne-related questions)
Number of subjects: 50
Study 25790848 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-dermatologic health-related questions)
Number of subjects: 50
Study 23480696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive triple analgesia (n = 55)
Number of subjects: 135
Study 23480696 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 80)
Number of subjects: 135
Study 21854365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single port laparoscopically assisted vaginal hysterectomy (SP-LAVH)
Number of subjects: 95
Study 21854365 — intervention group
Group type: COMPARATOR
Intervention: Conventional multiport laparoscopically assisted vaginal hysterectomy (conventional LAVH)
Number of subjects: 95
Study 19571727 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 875
Study 19571727 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-8
Number of subjects: 875
Study 17426275 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone
Number of subjects: 241
Study 17426275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 17426275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 241
Study 17426275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Placebo
Number of subjects: 241
Study 15274404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine (CG) - gemcitabine 1125 mg/m2 (days 1 and 8) plus cisplatin 80 mg/m2 (day 2) every 3 weeks for a maximum of 5 cycles
Number of subjects: 69
Study 15274404 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-gemcitabine (EG) - gemcitabine 1125 mg/m2 (days 1 and 8) plus epirubicin 100 mg/m2 (day 1) every 3 weeks for a maximum of 5 cycles
Number of subjects: 69
Study 11534915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.02%
Number of subjects: 2
Study 11534915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 2
Study 9807989 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha2b plus ribavirin for 48 weeks
Number of subjects: 832
Study 9807989 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha2b plus ribavirin for 24 weeks
Number of subjects: 832
Study 9807989 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha2b plus placebo for 48 weeks
Number of subjects: 832
Study 7700785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Number of subjects: 0
Study 7700785 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium and bupivacaine hydrochloride
Number of subjects: 0
Study 7700785 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride (alone)
Number of subjects: 0
Study 2791714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g single pre‐operative dose, continued daily for 5 days in perforated appendicitis)
Number of subjects: 200
Study 2791714 — intervention group
Group type: COMPARATOR
Intervention: Triple regimen (metronidazole, gentamicin, and ampicillin, given every 8 hours for 3 days, extended to 5-7 days in cases of perforation)
Number of subjects: 200
Study 2791714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 200
Study 2791714 — intervention group
Group type: COMPARATOR
Intervention: Triple regimen
Number of subjects: 200
Study 196421 — intervention group
Group type: EXPERIMENTAL
Intervention: LUPIDON H or LUPIDON G
Number of subjects: 100
Study 196421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30922885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-point Likert scale
Number of subjects: 57
Study 30922885 — intervention group
Group type: COMPARATOR
Intervention: Three-point Likert scale
Number of subjects: 57
Study 27967281 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution (MAL)
Number of subjects: 18
Study 27967281 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.1% glucose solution (GLU)
Number of subjects: 18
Study 27967281 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (W)
Number of subjects: 18
Study 27967281 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially sweetened solution (PLA)
Number of subjects: 18
Study 27967281 — intervention group
Group type: COMPARATOR
Intervention: Control trial with no rinse (CON)
Number of subjects: 18
Study 25557776 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training twice daily for 5 days, concurrent with CPM therapy
Number of subjects: 66
Study 25557776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback intervention)
Number of subjects: 66
Study 23158522 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 4.5 mg/m² per day (titrated to achieve blood trough concentrations of 5-15 ng/mL)
Number of subjects: 117
Study 23158522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 23158522 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 117
Study 22082247 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigning Daily Occupations program
Number of subjects: 42
Study 22082247 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual
Number of subjects: 42
Study 19525739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT) - antidepressants and body‐mind‐spirit group psychotherapy
Number of subjects: 36
Study 19525739 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (MT) - antidepressants only
Number of subjects: 36
Study 19525739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT)
Number of subjects: 36
Study 19525739 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (MT)
Number of subjects: 36
Study 16755179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 471
Study 16755179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during pre-test)
Number of subjects: 471
Study 16755179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest characteristics (married, employed, worried about breast cancer, received annual physical examination)
Number of subjects: 471
Study 16755179 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups
Number of subjects: 471
Study 15774356 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential Training
Number of subjects: 50
Study 15774356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Training
Number of subjects: 50
Study 15774356 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 50
Study 15577166 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary calcium
Number of subjects: 0
Study 15577166 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11198056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin 100 mg
Number of subjects: 12
Study 11198056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg
Number of subjects: 12
Study 11198056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9331213 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 79
Study 9331213 — intervention group
Group type: COMPARATOR
Intervention: Acrylic IOL
Number of subjects: 79
Study 8447614 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding for three days
Number of subjects: 62
Study 8447614 — intervention group
Group type: COMPARATOR
Intervention: No enteral feeding for three days
Number of subjects: 62
Study 8447614 — intervention group
Group type: EXPERIMENTAL
Intervention: Second randomisation to enteral feeding for three days
Number of subjects: 62
Study 8447614 — intervention group
Group type: COMPARATOR
Intervention: Second randomisation to no enteral feeding for three days
Number of subjects: 62
Study 3828485 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administered rectally (80 mg)
Number of subjects: 8
Study 3828485 — intervention group
Group type: COMPARATOR
Intervention: Propranolol administered orally (80 mg)
Number of subjects: 8
Study 3828485 — intervention group
Group type: COMPARATOR
Intervention: Propranolol administered intravenously (2.2 mg)
Number of subjects: 8
Study 2910963 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow excision (1-cm margins)
Number of subjects: 612
Study 2910963 — intervention group
Group type: COMPARATOR
Intervention: Wide excision (3 cm or more margins)
Number of subjects: 612
Study 31054062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 31
Study 31054062 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 31
Study 31394146 — intervention group
Group type: EXPERIMENTAL
Intervention: ARK intervention (Antibiotic Review Kit)
Number of subjects: 588
Study 31394146 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation
Number of subjects: 588